Project News

The B2B Consortium collects the excellence of several sectors, each one contributing to a specific component of the device. Only the synergy between all the parts gives life to the B2B device. The realization of the breast cancer model from a patient-derived primary lesion is led by Nicola Aceto at the Cancer Metastasis lab of the University of Basel, winner…

Unable to validate some of their hypothesis, scientists often remain with many pending questions about cancer, especially regarding the metastatic process and the failure of preclinical studies: how come that some cancer cells exit the site of origin, enter the blood flow and attack another tissue? Why certain drugs do not have the expected effect in patients compared to pre-clinical…

Research, in order to advance and fuel innovation, needs technological innovation itself. The EU-funded project B2B is doing research for researchers, to bring recent advances in fluidic systems and 3D printing to the biomedical sector. “When a new technology reaches the biomedical field, all eyes are on the technology and its advantages – but to have a successful uptake, the…

B2B it’s a Future & Emerging Technologies (FET) project. This EU-funded Programme is all about transforming advanced scientific ideas into radically new technologies for the future. As for the B2B platform, the breakthrough technology should not be incremental but truly revolutionary, changing the today paradigms. We asked our project coordinator Silvia Scaglione to describe the innovation behind B2B and why…

B2B project has officially started on July 1, 2018. During the next 4 years, the Consortium will be busy developing a novel hybrid device able to model the spontaneous breast cancer metastasis to the bone. The project has been funded for a total of 3.8M€ under the FET OPEN call of the European Union’s Horizon 2020 Framework Programme. The full official information…

This project has received funding from the European Union's Horizon 2020 research and innovation programme under the grant agreement No 801159